ArticlePloS one2026
Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform.
Hannah R Volkman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.